Fig. 3 | Scientific Reports

Fig. 3

From: PRSS22 as a novel prognostic and immune regulatory biomarker in PanCancer multiomics analysis

Fig. 3The alternative text for this image may have been generated using AI.

Prognostic and diagnostic value of PRSS22 expression across cancers. (A) Forest plot depicting the association between PRSS22 expression and OS in a pan-cancer analysis (Cox proportional hazards model) (B) Kaplan–Meier survival curves showing the impact of high versus low PRSS22 expression on OS in four representative cancers: KIRC, LIHC, LUAD, and SKCM. (C) Diagnostic efficacy of PRSS22 expression in prognosis-linked cancers assessed via ROC curves.

Back to article page